Key result
Homocysteine directly inhibits endothelial thrombomodulin cofactor activity by ~90%.
Why the study?
Does homocysteine inhibit the cofactor activity of thrombomodulin in human umbilical vein endothelial cells?
Population
Human umbilical vein endothelial cells (HUVECs) and purified thrombomodulin
Comparison
Homocysteine incubation for up to 24 hours vs Untreated cells or purified thrombomodulin
Design
Preclinical
Follow-up
up to 24 hours
Authors
Loading...
May impair endothelial antithrombotic function in hyperhomocysteinemia; leaves open human relevance and therapeutic implications.
Does homocysteine inhibit the cofactor activity of thrombomodulin in human umbilical vein endothelial cells?
Homocysteine directly inhibits the cofactor activity of thrombomodulin on endothelial cells, which may reduce the antithrombotic properties of the endothelium and contribute to atherothrombotic disease.
Hayashi et al. (1992) studied this question. Homocysteine was evaluated on Cofactor activity of thrombomodulin. Homocysteine directly inhibited the cofactor activity of thrombomodulin on endothelial cells, reducing it to 10% of initial activity after 3 to 6 hours of incubation with 10 mmol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: